[go: up one dir, main page]

AR011503A1 - Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas - Google Patents

Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas

Info

Publication number
AR011503A1
AR011503A1 ARP970101580A ARP970101580A AR011503A1 AR 011503 A1 AR011503 A1 AR 011503A1 AR P970101580 A ARP970101580 A AR P970101580A AR P970101580 A ARP970101580 A AR P970101580A AR 011503 A1 AR011503 A1 AR 011503A1
Authority
AR
Argentina
Prior art keywords
alkyl
branched
unbranched
esters
phenyl
Prior art date
Application number
ARP970101580A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27092026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011503(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/833,271 external-priority patent/US5998402A/en
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR011503A1 publication Critical patent/AR011503A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto seleccionado de las formulas I o II: donde R1 se selecciona de H, OH o de los ésteres C1-C12 (de cadena ramificada o no ramificada) o susalquil ésteres C1-C12 (de cadena ramificada o no ramificada o cíclica), o halogenos; oésteres halogenados C1-C4 que incluyen al trifluorometil éter ytriclorometil éter. R2, R3, R4, R5 y R6 se seleccionan independientemente de H, OH o ésteres de C1-C12(de cadena raqmificada o no ramificada o cíclica),halogenos o ésteres C1-C4halogenados incl uyendo al trifluorometil éter, ciano, alquil C1-C6(de cadena ramificada o no ramificada), o trifluorometil, con lacondicion de que cuando R1 es H, R2 no sea OH: X se selecciona de H, alquil C1-C6, ciano, nitro, trifluorometil,halogeno; n es 2 o 3; Y se selecciona de:a) la porcion (formula 3) donde R7 y R8 se seleccionan independientemente del grupo H, alquilo C1-C6, o fenilo opcionalmente sustituido por CN, alquilo C1-C6(de cadena ramificada o no ramificada), alcoxi C1- C6( de cadena ramif icada o no ramificada), halogeno, -OH, -CF3, o -OCF3; b)un heterociclo de cinco miembrossaturados, o no saturados o parcialmente no saturado que contiene hasta dos heteroátomos seleccionados del grupo formado por -O-, -NH-, - N(alquilo C1-C4)-,-N= y -S(O)m-, donde m es un entero entre 0-2, opcionalmente sustituido con 1-3 sustituyentes independientemente seleccionados del grupo formado porhidrogeno, hidroxilo, halo, alquilo C1-C4, trihalometilo, alcoxi C1-C4,trihalometoxi, acilox i C1-C4, alquiltio C1-C4, alquilsulfinil C1-C4,alquilsulfonil C1-C4, hidroxi alquilo (C1-C4), -CO2H-, -CN-, -CONHR1-, -NH2-, alquilamino C1-C4, dialquilamino (C1-C4), -CO2H-, -CN-, -CONHR1-, -NH2-,alquilamino C1-C4,dialquilamino (C1-C4), -NHSO2R1- , -NHCOR1-, -NO2, y fenilo opcionalmente sustituido con 1-3 alquilo (C1-C4); c) un heterociclo de seis
ARP970101580A 1996-04-19 1997-04-18 Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas AR011503A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397496A 1996-04-19 1996-04-19
US08/833,271 US5998402A (en) 1996-04-19 1997-04-04 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents

Publications (1)

Publication Number Publication Date
AR011503A1 true AR011503A1 (es) 2000-08-30

Family

ID=27092026

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101580A AR011503A1 (es) 1996-04-19 1997-04-18 Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas

Country Status (26)

Country Link
EP (1) EP0802183B1 (es)
JP (1) JP4093611B2 (es)
KR (1) KR100480193B1 (es)
CN (1) CN1106383C (es)
AR (1) AR011503A1 (es)
AT (1) ATE206701T1 (es)
AU (1) AU710149B2 (es)
BR (1) BRPI9715334B8 (es)
CO (1) CO4900051A1 (es)
CY (2) CY2325B1 (es)
CZ (1) CZ291701B6 (es)
DE (2) DE69707189T2 (es)
DK (1) DK0802183T3 (es)
EA (1) EA001448B1 (es)
ES (1) ES2162198T3 (es)
FR (1) FR09C0048I2 (es)
HU (1) HU227077B1 (es)
IL (1) IL120701A (es)
LU (1) LU91608I2 (es)
MX (1) MX9702865A (es)
NL (1) NL300416I2 (es)
NO (2) NO309564B1 (es)
NZ (1) NZ314601A (es)
PT (1) PT802183E (es)
SK (1) SK281737B6 (es)
UA (1) UA48148C2 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287980A1 (en) * 1997-04-30 1998-11-05 Daniel Jon Sall Antithrombotic agents
EP1019047B1 (en) 1997-05-01 2003-11-05 Eli Lilly And Company Antithrombotic agents
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
CA2331631A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation Benzocarbazoles and indenoindoles as estrogenic agents
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
JP2002515431A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション エストロゲンと組み合わせる2−フェニル−1−[4−(2−アミノエトキシ)ベンジルオキシ]インドール
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ATE258934T1 (de) 1998-10-30 2004-02-15 Lilly Co Eli Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
TWI220898B (en) * 1999-03-04 2004-09-11 Wyeth Corp N-substituted indolines as estrogenic agents
EP1159268A1 (en) * 1999-03-04 2001-12-05 American Home Products Corporation N-SUBSTITUTED BENzOYL INDOLES AS ESTROGENIC AGENTS
US6380185B1 (en) 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
US6358943B1 (en) 1999-03-04 2002-03-19 American Home Products Corporation N-substituted indolines as estrogenic agents
KR100653570B1 (ko) * 1999-09-13 2006-12-05 와이어쓰 2-(4-하이드록시-페닐)-1-[4-(2-아민-1-일-에톡시)-벤질]-1h-인돌-5-올의 글루코피라노시드 접합체
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
SK9592002A3 (en) * 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20020016318A1 (en) * 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
CA2414111A1 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
WO2002003990A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
WO2002003975A2 (en) 2000-07-06 2002-01-17 Wyeth Combinations of ssri and estrogenic agents
US6358991B2 (en) * 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
AU2001271781A1 (en) * 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
ES2259376T3 (es) 2001-05-22 2006-10-01 Eli Lilly And Company 1,2,3,4-tetrahidroquinolinas 2-sustituidas y sus derivados, composiciones y procedimientos.
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
AU2003248707A1 (en) * 2002-06-13 2003-12-31 Wyeth Bazedoxifene treatment regimens
BR0312675A (pt) 2002-07-22 2005-05-03 Lilly Co Eli Composto ou um sal de adição de ácido farmacêutico do mesmo,m e, métodos para tratar endometriose, e para tratar leiomioma uterino
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
PA8629201A1 (es) 2004-04-07 2005-11-25 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
US7683051B2 (en) 2004-04-07 2010-03-23 Wyeth Crystalline polymorph of bazedoxifene acetate
MXPA06011686A (es) 2004-04-08 2006-12-14 Wyeth Corp Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo.
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. C형 간염 치료 방법
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
WO2006017639A2 (en) * 2004-08-05 2006-02-16 Wyeth Crystalline polymorph of pipindoxifene hydrochloride monohydrate
CN106138065A (zh) 2004-10-20 2016-11-23 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
JP5199395B2 (ja) * 2008-02-11 2013-05-15 ワイス・エルエルシー バゼドキシフェン酢酸塩の多形体aの調製方法
HUE025471T2 (hu) 2008-04-16 2016-03-29 Karobio Ab Új ösztrogén receptor ligandumok
US20120253038A1 (en) * 2009-04-13 2012-10-04 Sandoz Ag Processes for the synthesis of bazedoxifene acetate and intermediates thereof
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
KR20140089402A (ko) 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US7968732B1 (en) 2010-09-07 2011-06-28 Divi's Laboratories, Ltd. Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole
WO2012037187A2 (en) 2010-09-14 2012-03-22 Dr. Reddy's Laboratories Ltd. Preparation of crystalline bazedoxifene and its salts
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
WO2014186325A1 (en) * 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
JP6807841B2 (ja) * 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
KR20190110400A (ko) 2018-03-20 2019-09-30 엠에프씨 주식회사 새로운 중간체를 이용한 바제독시펜의 제조방법
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU385443A3 (es) * 1970-01-21 1973-05-29
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
EP0634169B1 (en) * 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
NO2009025I1 (no) 2009-11-30
NZ314601A (en) 1999-09-29
NO971815D0 (no) 1997-04-18
MX9702865A (es) 1998-05-31
CY2325B1 (en) 2003-11-14
PT802183E (pt) 2002-03-28
NO971815L (no) 1997-10-20
HUP9700777A2 (hu) 1999-06-28
IL120701A0 (en) 1997-09-30
NO309564B1 (no) 2001-02-19
FR09C0048I1 (es) 2009-06-11
HK1002863A1 (en) 1998-09-25
CO4900051A1 (es) 2000-03-27
NO2009025I2 (no) 2010-11-22
CY2009016I1 (el) 2010-07-28
BR9715334B1 (pt) 2012-09-04
IL120701A (en) 2005-09-25
HUP9700777A3 (en) 2000-04-28
DE122009000061I1 (de) 2009-12-31
CY2009016I2 (el) 2010-07-28
JPH1036346A (ja) 1998-02-10
SK47297A3 (en) 1997-11-05
CN1106383C (zh) 2003-04-23
HU227077B1 (en) 2010-06-28
DE69707189D1 (de) 2001-11-15
AU1892097A (en) 1997-10-23
UA48148C2 (uk) 2002-08-15
SK281737B6 (sk) 2001-07-10
CZ117597A3 (en) 1997-11-12
KR100480193B1 (ko) 2005-08-30
KR970069037A (ko) 1997-11-07
DE69707189T2 (de) 2002-06-20
AU710149B2 (en) 1999-09-16
EA001448B1 (ru) 2001-04-23
CN1170719A (zh) 1998-01-21
HU9700777D0 (en) 1997-06-30
DK0802183T3 (da) 2002-02-04
FR09C0048I2 (es) 2010-06-11
ATE206701T1 (de) 2001-10-15
ES2162198T3 (es) 2001-12-16
CZ291701B6 (cs) 2003-05-14
NL300416I1 (nl) 2009-12-01
EP0802183B1 (en) 2001-10-10
EA199700044A1 (ru) 1997-12-30
LU91608I2 (fr) 2009-11-23
JP4093611B2 (ja) 2008-06-04
BRPI9715334B8 (pt) 2021-05-25
NL300416I2 (nl) 2010-02-01
EP0802183A1 (en) 1997-10-22

Similar Documents

Publication Publication Date Title
AR011503A1 (es) Derivados de 2-fenil-1-[4-(2-aminoetoxi)-bencil]-indol, un proceso para su preparacion ,composicion farmaceutica que los contiene y uso del mismo para preparar composiciones farmaceuticas
AR006705A1 (es) Compuestos de 3-[4-(2-fenil-indol-1-ilmetil)-fenil]-acrilamida y 2-fenil-1-[4-(amino-1-il-alqu-1-inil)-bencil]-1h-indol-5-ol, metodo para preparar medicamentos y composiciones farmaceuticas que los contiene
ES2033423T3 (es) Procedimientos para preparar derivados de 2-fenilpurinona.
ES2100151T3 (es) Nuevos derivados de benzopirano, procedimientos para su preparacion y su uso y composiciones que contienen los compuestos.
AR030064A1 (es) Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
UY24555A1 (es) Nuevos compuestos
EA200200360A1 (ru) Производные пурина
ATE29255T1 (de) Succinimid-derivate und deren herstellung.
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
AR015183A1 (es) Ariloxi-alquil-dialquilaminas y procesos para su produccion
SE8200916L (sv) Karbostyrilderivat, forfarande for framstellning derav och hjertsterkande komposition som innehaller detsamma
ES526318A0 (es) Procedimiento para la obtencion de derivados de 1-hidroxietil-triazolilo sustituidos
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
DK71780A (da) Fremgangsmaade til fremstilling af difenylhydantoinderivater
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
AU643290B2 (en) Derivatives of 2-aminoalkyl-5-arylalkyl-1,3-dioxanes, their preparation and their therapeutic application
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
AR022797A1 (es) Benzoil indoles n-sustituidos como agentes estrogenicos
ES2052266T3 (es) Empleo de mezclas de poliglicoleteres como antiespumantes.
AR021455A1 (es) Composicion farmaceutica de 2-fenil-1-[4-(amino-1-il-alc-1-inil)-bencil]-1h-indol-5-ol y estrogeno y su uso para la manufactura de un medicamento
AR018350A1 (es) Indenoindoles y benzocarbazoles y su uso para la manufactura de un medicamento
AR018349A1 (es) Composicion farmaceutica que comprende estrogenos y antiestrogenos y su uso para la manufactura de un medicamento
SE7710958L (sv) Sett att framstella biologiskt aktiva tetracykliska foreningar
ES527550A0 (es) Procedimiento para la preparacion de derivados de acridanona

Legal Events

Date Code Title Description
FG Grant, registration